Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

Published on Aug 10, 2017in Journal of Clinical Oncology32.956
· DOI :10.1200/JCO.2017.73.9987
Wanling Xie51
Estimated H-index: 51
(European Organisation for Research and Treatment of Cancer),
Meredith M. Regan85
Estimated H-index: 85
(European Organisation for Research and Treatment of Cancer)
+ 14 AuthorsChristopher Sweeney77
Estimated H-index: 77
(Harvard University)
PurposeAdjuvant therapy for intermediate-risk and high-risk localized prostate cancer decreases the number of deaths from this disease. Surrogates for overall survival (OS) could expedite the evaluation of new adjuvant therapies.MethodsBy June 2013, 102 completed or ongoing randomized trials were identified and individual patient data were collected from 28 trials with 28,905 patients. Disease-free survival (DFS) and metastasis-free survival (MFS) were determined for 21,140 patients from 24 trials and 12,712 patients from 19 trials, respectively. We evaluated the surrogacy of DFS and MFS for OS by using a two-stage meta-analytic validation model by determining the correlation of an intermediate clinical end point with OS and the correlation of treatment effects on both the intermediate clinical end point and OS.ResultsTrials enrolled patients from 1987 to 2011. After a median follow-up of 10 years, 45% of 21,140 men and 45% of 12,712 men experienced a DFS and MFS event, respectively. For DFS and MFS, 61% ...
📖 Papers frequently viewed together
499 Citations
420 Citations
778 Citations
#1William U. Shipley (Harvard University)H-Index: 100
#2W. SeiferheldH-Index: 18
Last. Howard M. SandlerH-Index: 96
view all 22 authors...
BackgroundSalvage radiation therapy is often necessary in men who have undergone radical prostatectomy and have evidence of prostate-cancer recurrence signaled by a persistently or recurrently elevated prostate-specific antigen (PSA) level. Whether antiandrogen therapy with radiation therapy will further improve cancer control and prolong overall survival is unknown. MethodsIn a double-blind, placebo-controlled trial conducted from 1998 through 2003, we assigned 760 eligible patients who had und...
315 CitationsSource
#1Freddie C. Hamdy (University of Oxford)H-Index: 94
#2Jenny L Donovan (UoB: University of Bristol)H-Index: 106
Last. David E. Neal (University of Cambridge)H-Index: 111
view all 27 authors...
BackgroundThe comparative effectiveness of treatments for prostate cancer that is detected by prostate-specific antigen (PSA) testing remains uncertain. MethodsWe compared active monitoring, radical prostatectomy, and external-beam radiotherapy for the treatment of clinically localized prostate cancer. Between 1999 and 2009, a total of 82,429 men 50 to 69 years of age received a PSA test; 2664 received a diagnosis of localized prostate cancer, and 1643 agreed to undergo randomization to active m...
1,319 CitationsSource
#1Ashley E. Ross (Johns Hopkins University)H-Index: 52
#2Kasra YousefiH-Index: 21
Last. Edward M. Schaeffer (Johns Hopkins University)H-Index: 59
view all 13 authors...
Abstract Background Current guidelines suggest adjuvant radiation therapy for men with adverse pathologic features (APFs) at radical prostatectomy (RP). We examine at-risk men treated only with RP until the time of metastasis. Objective To evaluate whether clinicopathologic risk models can help guide postoperative therapeutic decision making. Design, setting, and participants Men with National Comprehensive Cancer Network intermediate- or high-risk localized prostate cancer undergoing RP in the ...
17 CitationsSource
#1Rebecca L. Siegel (ACS: American Cancer Society)H-Index: 67
#2Kimberly D. Miller (ACS: American Cancer Society)H-Index: 28
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 139
view all 3 authors...
Abstract Each year, the American Cancer Society estimates the numbers of new cancer cases and deaths that will occur in the United States in the current year and compiles the most recent data on cancer incidence, mortality, and survival. Incidence data were collected by the National Cancer Institute (Surveillance, Epidemiology, and End Results [SEER] Program), the Centers for Disease Control and Prevention (National Program of Cancer Registries), and the North American Association of Central Can...
11.8k CitationsSource
New systemic therapies have prolonged the lives of men with metastatic castration-resistant prostate cancer (mCRPC). Use of these therapies in the adjuvant setting when the disease may be micrometastatic and potentially more sensitive to therapies may decrease mortality from prostate cancer. However, the conduct of adjuvant prostate cancer clinical trials is hampered by taking longer than a decade to reach the meaningful endpoint of overall survival (OS) and the fact that many men never die from...
40 CitationsSource
#1Lindsey A. Torre (ACS: American Cancer Society)H-Index: 16
#2Freddie Bray (IARC: International Agency for Research on Cancer)H-Index: 119
Last. Ahmedin Jemal (ACS: American Cancer Society)H-Index: 139
view all 6 authors...
Cancer constitutes an enormous burden on society in more and less economically developed countries alike. The occurrence of cancer is increasing because of the growth and aging of the population, as well as an increasing prevalence of established risk factors such as smoking, overweight, physical inactivity, and changing reproductive patterns associated with urbanization and economic development. Based on GLOBOCAN estimates, about 14.1 million new cancer cases and 8.2 million deaths occurred in ...
18.1k CitationsSource
#1Oriana Ciani (University of Exeter)H-Index: 20
#2Sarah Davis (University of Sheffield)H-Index: 31
Last. Rod S Taylor (University of Exeter)H-Index: 104
view all 9 authors...
Objectives: Licensing of, and coverage decisions on, new therapies should rely on evidence from patient-relevant endpoints such as overall survival (OS). Nevertheless, evidence from surrogate endpoints may also be useful, as it may not only expedite the regulatory approval of new therapies but also inform coverage decisions. It is, therefore, essential that candidate surrogate endpoints be properly validated. However, there is no consensus on statistical methods for such validation and on how th...
45 CitationsSource
#1Anna Bill-AxelsonH-Index: 27
#2Lars Holmberg ('KCL': King's College London)H-Index: 103
Last. Jan-Erik JohanssonH-Index: 60
view all 15 authors...
During 23.2 years of follow-up, 200 of 347 men in the surgery group and 247 of the 348 men in the watchful-waiting group died. Of the deaths, 63 in the surgery group and 99 in the watchful-waiting group were due to prostate cancer; the relative risk was 0.56 (95% confidence interval [CI], 0.41 to 0.77; P = 0.001), and the absolute difference was 11.0 percentage points (95% CI, 4.5 to 17.5). The number needed to treat to prevent one death was 8. One man died after surgery in the radicalprostatect...
675 CitationsSource
#2Xian Chong ZhouH-Index: 2
Last. Emmanuel S. AntonarakisH-Index: 63
view all 8 authors...
single institution between 1981 and 2010, of which 140 developed subsequent metastases. Androgen deprivation therapy (ADT) was deferred until after the development of metastases. Cox regression models were developed to investigate factors influencing OS. Results: Median metastasis-free survival (MFS) was 10.2 years [95% confidence interval (CI) 7.6–14.0 years]; median OS after metastasis was 6.6 years (95%CI 5.8–8.4 years). Multivariable Cox regressions identified four independently prognostic v...
81 CitationsSource
#1Juanita CrookH-Index: 16
#1Juanita CrookH-Index: 1
Last. L. KlotzH-Index: 13
view all 21 authors...
BACKGROUND Intermittent androgen deprivation for prostate-specific antigen (PSA) elevation after radiotherapy may improve quality of life and delay hormone resistance. We assessed overall survival with intermittent versus continuous androgen deprivation in a noninferiority randomized trial. METHODS We enrolled patients with a PSA level greater than 3 ng per milliliter more than 1 year after primary or salvage radiotherapy for localized prostate cancer. Intermittent treatment was provided in 8-mo...
326 CitationsSource
Cited By180
#1Igor TsaurH-Index: 22
#2Isabel Heidegger (Innsbruck Medical University)H-Index: 21
Last. Eliott Debedde (Paris V: Paris Descartes University)
view all 24 authors...
BACKGROUND Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone-sensitive prostate cancer (mHSPC). Real-world data comparing different protocols are lacking yet. Thus, our objective was to compare the efficacy and safety of abiraterone acetate (AA)+ADT versus D+ADT in mHSPC. METHODS In a retrospective multicenter analysis including males with mHSPC treated with either of the...
#1Isabelle R. Weir (BU: Boston University)
#2Jennifer R. RiderH-Index: 28
Last. Ludovic Trinquart (Tufts University)H-Index: 53
view all 3 authors...
In cancer randomized controlled trials, surrogate endpoints are frequently time-to-event endpoints, subject to the competing risk from the time-to-event clinical outcome. In this context, we introduce a counterfactual-based mediation analysis for a causal assessment of surrogacy. We use a multistate model for risk prediction to account for both direct transitions towards the clinical outcome and indirect transitions through the surrogate outcome. Within the counterfactual framework, we define na...
#2Ugo De GiorgiH-Index: 55
Last. Neal D. ShoreH-Index: 56
view all 8 authors...
INTRODUCTION Limited data from controlled clinical trials are available for men who experience biochemical recurrence after definitive therapy for prostate cancer. In the absence of overt metastases, patients with non-metastatic castration-sensitive prostate cancer (nmCSPC) often receive androgen deprivation therapy (ADT). There is no standard-of-care consensus on optimal ADT timing, although most men are treated prior to metastases, especially those with high-risk features (Gleason score 8-10 o...
#1Gert De Meerleer (Katholieke Universiteit Leuven)H-Index: 36
#2Charlien Berghen (Katholieke Universiteit Leuven)H-Index: 6
Last. Kato Rans (Katholieke Universiteit Leuven)H-Index: 2
view all 13 authors...
In patients with prostate cancer who have a high risk of pelvic nodal disease, the use of elective whole pelvis radiotherapy is still controversial. Two large, randomised, controlled trials (RTOG 9413 and GETUG-01) did not show a benefit of elective whole pelvis radiotherapy over prostate-only radiotherapy. In 2020, the POP-RT trial established the role of elective whole pelvis radiotherapy in patients who have more than a 35% risk of lymph node invasion (known as the Roach formula). POP-RT stre...
#1Michel Bolla (Centre Hospitalier Universitaire de Grenoble)H-Index: 56
#2Anouk NevenH-Index: 3
Last. John Armstrong (Mount Sinai St. Luke's and Mount Sinai Roosevelt)H-Index: 16
view all 22 authors...
PURPOSEThe European Organisation for Research and Treatment of Cancer (EORTC) trial 22991 (NCT00021450) showed that 6 months of concomitant and adjuvant androgen suppression (AS) improves event- (E...
#1Gerhardt Attard (UCL: University College London)H-Index: 75
#2Louise Brown (UCL: University College London)H-Index: 14
Last. Nicholas D. James (The Royal Marsden NHS Foundation Trust)H-Index: 66
view all 5 authors...
#1Christoph Würnschimmel (UdeM: Université de Montréal)H-Index: 3
Last. Derya TilkiH-Index: 57
view all 8 authors...
The proposed international staging collaboration for cancer of the prostate (STAR-CAP) clinical prognostic system for prostate cancer predicts cancer-specific mortality (CSM) for patients for whom active treatment, such as radical prostatectomy (RP), is planned. Until now, no validation of STAR-CAP has been performed. We retrospectively analyzed data from our institutional database for 19 552 patients treated with RP between 1992 and 2015. We applied the STAR-CAP point assignment criteria to cal...
#1Rachel Glicksman (Princess Margaret Cancer Centre)
#2Alejandro Berlin (UHN: University Health Network)H-Index: 17
Abstract null Objectives null The use of surrogate endpoints (SEs) for cancer drug approval in health systems is common. The objectives of this study were to identify systematic reviews (SRs) that evaluated the correlation of SEs with overall survival (OS) in cancer drugs to analyze the applications of approved cancer drugs with SEs in Mexico and to apply the validation framework proposed by the Institute for Quality and Efficiency in Health Care (IQWiG). null Methods null An overview of SRs was...
#1Vedang Murthy (HBNI: Homi Bhabha National Institute)H-Index: 6
#1Vedang Murthy (HBNI: Homi Bhabha National Institute)H-Index: 26
Last. Priyamvada Maitre (HBNI: Homi Bhabha National Institute)H-Index: 2
view all 2 authors...
1 CitationsSource